About the Authors
- Evan L. Brittain
-
* E-mail: evan.brittain@vanderbilt.edu
Affiliation Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
- Meredith E. Pugh
-
Affiliation Division of Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
- Li Wang
-
Affiliation Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
- Alex L. Newman
-
Affiliation Division of Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
- Ivan M. Robbins
-
Affiliation Division of Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
- John H. Newman
-
Affiliation Division of Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
- Anna R. Hemnes
-
Affiliation Division of Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
Competing Interests
MEP has performed consulting: Gilead; ARH has funding from Pfizer, United Therapeutics, and consulting: Actelion, United Therapeutics and Pfizer. ELB, LW, AN, IMR, and JHN all report no competing interests. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: EB MP LW AN IR JN AH. Performed the experiments: EB MP AN AH. Analyzed the data: EB MP LW AH. Contributed reagents/materials/analysis tools: EB MP LW AH. Wrote the manuscript: EB MP LW AN JN AH.